Healium Medical and the EIC Accelerator: Ultrasound Ablation
Atrial fibrillation, an irregular heartbeat, is often treated by ablation: a catheter destroys the heart tissue around the pulmonary veins that triggers it. Healium Medical, a company in Yokneam, Israel, is developing Echomplish, a catheter system that uses ultrasound in two modes, first to image the target and then to ablate it without touching the tissue.
The European Innovation Council granted €2,500,000 towards an €11.37 million project, DMUT, that ran from September 2022 to August 2025. By its end the system had created more than 100 lesion points in animal studies, but no clinical study had begun by the project end, and the CORDIS report says continuing requires "additional financing". Healium's latest post located on 3 November 2026, from February 2025, describes its "pre-clinical journey".
Company file
- Legal entity
- Healium Medical Ltd., Yokneam, Israel
- CEO
- Ran Sela, co-founder
- Chair
- Shimon Eckhouse, founder of Lumenis and Syneron
- Product
- Echomplish dual-mode ultrasound ablation system
- Indications
- Atrial fibrillation; hypertension listed
- Stage
- Preclinical
- EIC project
- DMUT, 1 Sep 2022 to 31 Aug 2025
- EIC funding
- Blended finance
Where Healium Stands Today
As of 3 November 2026, the latest post located on Healium's news page was a February 2025 image of "a defining moment in our pre-clinical journey with Echomplish". An earlier post announced the company's selection as a finalist in MedTech Innovator Asia-Pacific 2024. Its about page lists the team and board and indications for atrial fibrillation and high blood pressure. Healium Medical described Echomplish as preclinical in that post. We found no registered clinical trial for Echomplish on ClinicalTrials.gov. CORDIS reports no clinical study had started by the project end in August 2025. No product marketing authorization was identified in the sources reviewed.
The Technology: Seeing and Treating With Sound
Healium's approach is "contactless" and "dual-mode": ultrasound is used both to see the target and to treat it. According to CORDIS, animal studies showed a "continuous lesion around the pulmonary vein" and imaging that could "locate the exact connection point between the vein and the atrium".
"Simplifying the rapid growing market of ablation procedures with advanced miniaturized ultrasound guided therapeutic technology."
Healium Medical websiteWhat the EIC Project Promised, and What CORDIS Shows
The EIC project
CORDIS EU contribution to an EUR 11.37M project
CORDIS records EUR 2.5M as the EU contribution and EUR 8.87M as other project costs. The remaining project costs are not necessarily Healium's own cash. Healium described its broader EIC Accelerator award as EUR 12.75M; sources do not reconcile all components or disbursement timing.
CORDIS project 190176001; Healium Medical release, Sep 2022. Values in EUR millions.
DMUT promised "easy to use, contactless dual-mode ultrasound technology for high accuracy treatment of atrial fibrillation, improving outcomes". CORDIS reports the animal results and a MedTech Innovator selection in 2023, and says the next steps are completing procedure development, collecting chronic evidence and finding "additional financing" before clinical studies.
The evidence
Preclinical evidence and project timing
CORDIS reports acoustic data for more than 100 lesion points in animal studies and no clinical study started by the project end. Lesion points and patient studies measure different things; zero refers to clinical studies begun by August 2025, not a current trial-status finding.
CORDIS project 190176001 results.
- A working prototypeDeliveredTested in animals.
- Imaging-guided ablationDeliveredContinuous lesions in animals.
- First-in-human studyNot shownNo study reported by project end.
- Improved patient outcomesNot shownNo patients treated.
What Has Happened Since the Award
The record
Still in animal studies
CORDIS says no clinical study had begun by the DMUT project end in August 2025 and further financing was needed. Startup Nation Central lists an EIC Fund round in September 2022; the current financing position is not established in sources reviewed.
- Oct 2021EIC Accelerator cut-offDMUT: contactless dual-mode ultrasound for atrial fibrillation
- Sep 2022EIC Fund financing listedStartup Nation Central records EIC Fund participation in a $10.25M round
- Sep 2022EIC project startsImaging and ablation from one ultrasound catheter€2.50M grant
- 2023MedTech InnovatorOne of four finalists of the 2023 cohort, per CORDIS
- Jan 2025Asia-Pacific finalistMedTech Innovator Asia-Pacific 2024
- Feb 2025PreclinicalEchomplish shown in pre-clinical work
- Aug 2025EIC project ends100+ lesion points in animals; clinical study not started
CORDIS; Healium Medical; Startup Nation Central.
The Money
The EIC selected Healium for blended finance. Startup Nation Central lists a September 2022 funding round with EIC Fund participation and an amount of $10.25 million. Healium separately described its EIC Accelerator award as EUR 12.75 million in a September 2022 company release; CORDIS records a EUR 2.5 million EU grant contribution to DMUT and total project costs of EUR 11.37 million. The public sources reviewed do not reconcile the currencies, package components or disbursement timing. The other project costs are not necessarily Healium's own cash. No later funding round was located in sources reviewed as of 3 November 2026; Israeli company records were not accessible for this article.
What cannot be checked
How much of the announced EIC equity component was disbursed, how the project costs were financed, and when Healium plans its first human study were not established in sources reviewed.
Why Europe Should Care
Ablation for atrial fibrillation is a large and growing procedure, as Healium itself notes, and a contactless system with built-in imaging could be simpler to use. But the EU's grant covered only a small share of a large preclinical budget, and the project ended without reaching patients.
What the project promised
Contactless dual-mode ultrasound for accurate treatment of atrial fibrillation, improving outcomes.
What the record shows
Animal studies with good lesions, no patients treated and a stated need for more money.
The Verdict
Preclinical at the end of the project
DMUT advanced the technology in animal studies, but no clinical study had begun by the project end. CORDIS says further financing is required before clinical studies; this describes the project report, not proof that Healium has no current funding. Startup Nation Central lists an EIC Fund funding round in September 2022.
Healium Medical has not been asked for comment for this article. It is based entirely on company statements and EU project data, linked throughout.
Industry
HealthMedical devices
- Focus
- Cardiovascular devices
- Technologies
- Ultrasound
- Catheter technology
- Keywords
- Atrial fibrillation
- Catheter ablation
- Electrophysiology
- Hypertension